Form 10-Q
VACCINEX, INC. filed this Form 10-Q on 08/14/2018
Document Outline
Entire Document (4720.6 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - VACCINEX, INC.
Page 3 - PART I - FINANCIAL INFORMATION
Page 4 - VACCINEX, INC.
Page 5 - VACCINEX, INC.
Page 6 - VACCINEX, INC.
Page 7 - VACCINEX, INC.
Page 8 - Basis of Presentation and Consolidation
Page 9 - Recent Accounting Pronouncements Not Yet Adopted
Page 10 - Compensation-Stock Compensation: Scope of Modification Accounting
Page 11 - N/A
Page 12 - N/A
Page 13 - Merck Sharp Dohme Corp.
Page 14 - Heptares Therapeutics, Ltd.
Page 15 - January 2017 Notes
Page 16 - Sublicense Termination Payments
Page 17 - Employee Equity Plans
Page 18 - Determination of Fair Value
Page 19 - Expected Volatility
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 24 - Company Overview
Page 25 - Financial Overview
Page 26 - Results of Operations
Page 27 - Change in fair value of derivative liabilities
Page 28 - Change in Fair Value of Derivative Liabilities
Page 29 - Cash Flows
Page 30 - Investing Activities.
Page 31 - Contractual Obligations
Page 32 - Recent Accounting Pronouncements Not Yet Adopted
Page 33 - Part II - OTHER INFORMATION
Page 34 - We will require additional capital to finance our operations, which may not be available to us on ac
Page 35 - Our ability to continue as a going concern will require us to obtain additional financing to fund ou
Page 36 - Risks Related to Our Business and Industry
Page 37 - If we experience delays in clinical testing, we will be delayed in obtaining approval of our product
Page 38 - We may not successfully identify, develop or commercialize potential product candidates.
Page 39 - We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in
Page 40 - We are subject to multiple manufacturing risks, any of which could substantially increase our costs
Page 41 - Even if our product candidates receive regulatory approval, they may still face future development a
Page 42 - One of the indications we are pursuing for our lead product candidate VX15 is for the treatment of H
Page 43 - Our failure to obtain regulatory approval in international jurisdictions would prevent us from marke
Page 44 - Our competitors may develop and market products or services that are less expensive, more effective,
Page 45 - We may not be able to achieve the benefits or synergistic effects of VX15 in combination with other
Page 46 - We do not currently have any sales, marketing or distribution experience or infrastructure and may r
Page 47 - Current and future legislation may increase the difficulty and cost for commercialization of our pro
Page 48 - If we are able to successfully commercialize any of our product candidates and if we participate in
Page 49 - Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
Page 50 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 51 - Risks Related to our Dependence on Third Parties
Page 52 - We may not succeed in establishing and maintaining additional collaborations, which could adversely
Page 53 - Risks Related to Intellectual Property
Page 54 - We may not be able to protect our intellectual property rights throughout the world.
Page 55 - Changes in patent law and legal precedent concerning patents could diminish the value of patents in
Page 56 - Obtaining and maintaining our patent rights depends on compliance with various different procedural,
Page 57 - Third parties may initiate legal proceedings against us alleging that we infringe their intellectual
Page 58 - We may be subject to claims by third parties asserting that our employees or we have misappropriated
Page 59 - We may sell additional equity or debt securities or enter into other arrangements to fund our operat
Page 60 - If securities or industry analysts do not publish research or publish inaccurate or unfavorable rese
Page 61 - We incur significant costs as a result of operating as a public company, and our management is requi
Page 62 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 63 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Page 64 - Item 6. Exhibits
Page 65 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer